Taspoglutide

 Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.[1][2]

Taspoglutide
Clinical data
Routes of
administration		subcutaneous
ATC code
  • none
Pharmacokinetic data
BioavailabilityN/A
Identifiers
CAS Number
  • 275371-94-3 ☒
PubChem CID
  • 56842233
ChemSpider
  • 32819947 check
UNII
  • 2PHK27IP3B
KEGG
  • D09723 ☒
Chemical and physical data
FormulaC152H232N40O45
Molar mass3339.763 g·mol−1
 ☒check (what is this?)  (verify)

Two phase II trials reported it was effective and well tolerated.[3]

Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009.[4] Preliminary results in early 2010 were favourable.[5] (At least one of the eight planned phase III trials had not started recruiting by end 2009.[6])

In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects.[7][8]

As of May 2013 no new trials had been registered.[9][needs update]

ChemistryEdit

Taspoglutide is the peptide with the sequence H2N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2.

In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.

ChemistryEdit

Taspoglutide was a promising Glucagon like Peptide one receptor agonist and Incretin mimetic. The short duration of action was likely it's demise.

This article uses material from the Wikipedia article
 Metasyntactic variable, which is released under the 
Creative Commons
Attribution-ShareAlike 3.0 Unported License.